- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.04. | OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024 | 262 | GlobeNewswire (Europe) | LONDON and NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory... ► Artikel lesen | |
| 09.04. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 02.04. | OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery | 172 | GlobeNewswire (Europe) | LONDON and NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory... ► Artikel lesen | |
| 29.03. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 25.03. | OKYO Pharma Ltd expected to post a loss of 11 cents a share - Earnings Preview | 1 | Reuters | ||
| 22.03. | Relief For Dry Eye Disease? OKYO Pharma's Candidate Shows Durable Pain Relief In Mid-Stage Study | 3 | Benzinga.com | ||
| 22.03. | OKYO Pharma gains after positive results from Phase 2 dry eye disease trial | 1 | Seeking Alpha | ||
| 22.03. | OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101 | 248 | GlobeNewswire (Europe) | Ocular Pain Relief showed statistically significant improvement as early as day 15 and the benefit was durable throughout the trial.Conjunctival Staining improved as early as day 29 with a durable benefit... ► Artikel lesen | |
| 21.03. | OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial | 198 | GlobeNewswire (Europe) | -Phase 2 OK-101 efficacy data to be released March 22nd, 2024-
-KOL Event to be held on April 9th, 2024 at 12 PM ET-
LONDON and NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited... ► Artikel lesen | |
| 20.03. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 20.03. | OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event | 174 | GlobeNewswire (Europe) | LONDON and NEW YORK, March 20, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory... ► Artikel lesen | |
| 09.02. | FDA approves OKYO Pharma's IND for NCP treatment trial | 2 | Investing.com | ||
| 09.02. | OKYO Pharma gains on receiving FDA nod of IND for OK-101 in neuropathic corneal pain | - | Seeking Alpha | ||
| 09.02. | OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain | 325 | GlobeNewswire (Europe) | OK-101 is the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain (NCP), a major unmet medical needThe initial... ► Artikel lesen | |
| 09.02. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 31.01. | OKYO Pharma expands Scientific Advisory Board | 2 | Investing.com | ||
| 31.01. | OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board | 267 | GlobeNewswire (Europe) | LONDON and NEW YORK, Jan. 31, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory... ► Artikel lesen | |
| 31.01. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 08.01. | OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease | 380 | GlobeNewswire (Europe) | Statistically significant drug effects were observed in FDA-recognized efficacy endpoints as early as the 15-day first visit after dosingStatistically significant improvement was observed in both a... ► Artikel lesen | |
| 05.01. | OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024 | 294 | GlobeNewswire (Europe) | LONDON and NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory... ► Artikel lesen |
Seite:
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,55 | -1,04 % | BioNTech: Alle Aktien verkaufen oder? | Richtig leiden müssen heute BioNTech-Aktionäre. In den Büchern steht für den Kurs nämlich ein Minus von rund zwei Prozent. Nur noch 81,45 EUR müssen nach diesem Abschlag für ein Wertpapier hingelegt... ► Artikel lesen | |
| MEDIGENE | 1,805 | -2,43 % | PTA-News: Medigene AG: Medigene präsentiert auf folgenden wissenschaftlichen Konferenzen | DJ PTA-News: Medigene AG: Medigene präsentiert auf folgenden wissenschaftlichen Konferenzen
Unternehmensmitteilung für den Kapitalmarkt
Planegg/Martinsried (pta/17.04.2024/12:00) - Die Medigene... ► Artikel lesen | |
| CUREVAC | 2,448 | +1,41 % | CureVac: Die Entscheidung fällt nächste Woche! | Arg strapaziert wurden zuletzt die Nerven von CureVac-Anteilseignern. So ergibt sich im Vergleich zur Vorwoche ein Minus von 2,95 Prozent. Insgesamt zwei der drei Handelstage beendete der Titel mit... ► Artikel lesen | |
| QIAGEN | 37,000 | +0,04 % | Kurs der Qiagen NV-Aktie verharrt auf Vortags-Niveau (38,605 €) | CODE Die Aktie notiert aktuell bei 38,60 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei dem Anteilsschein von Qiagen NV. Das Papier weist gegenwärtig nur einen geringen Preisanstieg... ► Artikel lesen | |
| AMGEN | 248,45 | +0,40 % | Amgen Aktie: Hoffnungsträger Tezspire trotz Studiendämpfer | Amgen lässt mit seinen Aktivitäten rund um das vielversprechende Medikament Tezspire aufhorchen. Trotz gemischter Ergebnisse in der Phase-2-Studie zur Behandlung von COPD, hat Wells Fargo das Rating... ► Artikel lesen | |
| NOVAVAX | 3,719 | +1,89 % | BRISANTE Meldung setzt Novavax Aktionäre unter Zugzwang. Bitte reagieren Sie jetzt sofort! | ||
| CRISPR THERAPEUTICS | 55,25 | 0,00 % | CRISPR Therapeutics' Options Frenzy: What You Need to Know | ||
| REGENERON PHARMACEUTICALS | 850,00 | +0,62 % | Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick | ||
| ORGANOVO | 1,106 | +1,28 % | Organovo, Inc.: Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo | SAN DIEGO, April 15, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches based on demonstration... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 10,360 | 0,00 % | Pre-market Movers: Macatawa Bank, Ryvyl, WiSA Technologies, Inovio Pharmaceuticals, Mobilicom | STOCKHOLM (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.55 A.M. ET).In the Green Macatawa Bank Corporation (MCBC) is up over 38%... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,494 | +1,88 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering | Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has entered into a securities purchase agreement with institutional investors, providing for the purchase... ► Artikel lesen | |
| INFLARX | 1,235 | +3,87 % | InflaRx: Bis 2026 durchfinanziert - Verlust gestiegen | Das Biotech-Unternehmen InflaRx meldet für das Geschäftsjahr 2023 einen Anstieg des Defizits vor Zinsen und Steuern von 32,2 Millionen Euro auf 44,9 Millionen Euro. Unter dem Strich steigt der Verlust... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 20,010 | -0,69 % | Intellia Therapeutics, Inc. - 8-K, Current Report | ||
| BIO-GATE | 1,030 | 0,00 % | BioGate Precision Medicine Corp.: A Global Milestone in Innovative Pancreatic Cancer Therapy | Suppression of pancreatic cancer and increased survival rates in animals implanted with human pancreatic cancer cells when treated with biologic agent BGX, a proprietary targeted therapy... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 4,472 | +4,07 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory Agency | RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted approval... ► Artikel lesen |
OKYO PHARMA LIMITED gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,220 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
